Drug News

Spasticity Market Likely to Exhibit Substantial Growth by 2032, Predicts DelveInsight

DelveInsight’s “Spasticity Market Insights” report offers a thorough understanding of the current treatment landscape, emerging drugs, market shares, and the anticipated market size for the period 2019 to 2032.

The analysis covers seven major markets, including the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Key Findings from the Report:

1.        Market Size and Growth:

•          The spasticity market in the 7MM reached USD 904 million in 2021.

•          Positive growth is expected at a significant Compound Annual Growth Rate (CAGR) throughout the study period (2019–2032).

2.        Spasticity Cases:

•          In 2021, the total reported cases of spasticity in the 7MM were 7.8 million.

•          A further increase in spasticity cases is anticipated by 2032.

3.        Leading Companies:

•          Key players in the spasticity market include Saol Therapeutics Inc, Jazz Pharmaceuticals, Supernus Pharmaceuticals, Inc., Solstice Neurosciences, Ipsen, Merz Pharmaceuticals GmbH, Motric Bio, SwanBio Therapeutics, Inc., among others.

•          These companies are actively developing novel drugs for spasticity, contributing to the evolving treatment landscape.

4.        Key Therapies:

•          Notable therapies for spasticity treatment include SL-1002, Nabiximols, MYOBLOC, IPN10200, NT 201, MTR-601, SBT101, and others.

Spasticity Overview:

Spasticity is a common issue in various neuromuscular disabilities, presenting differently among individuals. Managing spasticity involves recognizing, evaluating, and addressing the condition. Conditions such as cerebral palsy, multiple sclerosis, and brain or spinal cord injuries commonly result in spasticity and involuntary muscle contractions. While existing treatments like baclofen effectively mitigate these contractions, abrupt cessation can lead to severe adverse effects.

  • Epidemiology Segmentation: The report provides insights into the historical and current spasticity patient pool and forecasted trends across the seven major countries. It includes segmentation based on total cases of spasticity, indication-specific cases, and severity-specific cases.
  • Spasticity Treatment Market: The management of spasticity involves various approaches, including non-medical interventions (physical therapy, occupational therapy), oral medications, and interventional therapies. Treatment patterns vary based on conditions, and a definitive cure is currently unavailable. Commonly prescribed antispasmodic medication includes oral baclofen, with alternative interventions considered in cases of undesirable side effects.
  • Market Dynamics: The dynamics of the spasticity market are expected to evolve, with a team-based approach and comprehensive assessment becoming crucial. The report suggests that treatment should be considered when there is a realistic chance of functional gain. While challenges such as contractures and reduced quality of life may arise, the future of spasticity treatment holds promising developments.

The report covers a study period from 2019 to 2032, providing coverage across the 7MM. Key metrics include the market size in 2021 (USD 904 million), key companies, and therapies. The scope encompasses therapeutic assessment, market dynamics, competitive intelligence analysis, and insights into unmet needs, KOL’s views, analyst’s views, market access, and reimbursement.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker